Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics

Blood

Volumn 105, Issue 7, 2005, Pages 2733-2740

  Fang, Baijun ^b   Zheng, Chunmei ^b   Liao, Lianming ^b   Han, Qin ^b   Sun, Zhao ^b   Jiang, Xueying ^b   Zhao, Robert C H ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INVASION; CELL POPULATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLONAL ANERGY; ENDOTHELIUM CELL; FETUS LIVER; FLUORESCENCE ACTIVATED CELL SORTING; FUSION GENE; GENE REARRANGEMENT; HEMANGIOBLASTOMA; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

EID: 15944364734     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2514     Document Type: Article

References (46)

1. Fialkow PJ. Clonal origin of human tumors. Biochim Biophys Acta. 1976;458:283-321.
2. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science. 1987;238:193-197.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
5. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst. 1971;46:411-422.
6. Al-Hajj M, Wicha MS, Benito-Hemandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-3988.
7. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 1994;70:6-22.
8. Mauro MJ, Druker BJ. Chronic myelogenous leukemia. Curr Opin Oncol. 2001;13:3-7.
9. Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 2000;355:1688-1691.
10. Guo H, Fang B, Zhao RC, et al. Hemangioblastic characteristics of fetal bone marrow-derived Flk1(+)CD31(-)CD34(-) cells. Exp Hematol. 2003;31:650-658.
11. Fang B, Shi M, Liao L, Yang S, Liu Y, Zhao RC. Multiorgan engraftment and multilineage differentiation by human fetal bone marrow Flk1 +/CD31-/CD34- progenitors. J Hematother Stem Cell Res. 2003;12:603-613.
12. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood. 2001;98:2615-2625.
13. Hoyle CF, Negrin RS. Engraftment of chronic myeloid leukemia in SCID mice. Hematol Oncol. 1998;16:87-100.
14. Thompson JD, Brodsky I, Yunis JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood. 1992;79:1629-1635.
15. Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med. 1989;169:1721-1731.
16. Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood. 1998;91:630-640.
17. Gallacher L, Murdoch B, Wu DM, Karanu FN, Keeney M, Bhatia M. Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood. 2000;95:2813-2820.
18. Eaves C, Fraser C, Udomsakdi C, et al. Manipulation of the hematopoietic stem cell in vitro. Leukemia. 1992;6(suppl 1):27-30.
19. Metcalf D. Hemopoietic colonies: in vitro cloning of normal and leukemic cells. Recent Results Cancer Res. 1977;61 Title page, 1-227.
20. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature. 1989;339:27-30.
21. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293:293-297.
22. McCulloch EA, Minden MD, Miyauchi J, Kelleher CA, Wang C. Stem cell renewal and differentiation in acute myeloblastic leukaemia. J Cell Sci Suppl. 1988;10:267-281.
23. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A. 1992;89:2804-2808.
24. Muench MO, Firpo MT, Moore MA. Bone marrow transplantation with interteukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood. 1993;81:3463-3473.
25. Griffin JD. Management of chronic myelogenous leukemia. Semin Hematol. 1986;23:20-26.
26. Talpaz M. Clinical studies of alpha-interferons in chronic myelogenous leukemia. Cancer Treat Rev. 1988;15(suppl A):49-53.
27. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
28. Cunningham I, Gee T, Dowling M, et al. Results of treatment of Ph' + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood. 1979;53:375-395.
29. Hester JP, Waddell CC, Coltman CA Jr, et al. Response of chronic myelogenous leukemia patients to COAP-splenectomy: a Southwest Oncology Group study. Cancer. 1984;54:1977-1982.
30. Dutcher JP, Lee S, Paietta E, Bennett JM, Stewart JA, Wiernik PH. Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia. 1998;12:1037-1040.
31. Cortes J, Kantarjian H, Talpaz M, et al. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia. 1997;11:788-791.
32. Cortes J, Kantarjian H, O'Brien S, et al. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia. 1997;11:929-932.
33. Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11:1617-1620.
34. Koeffler HP, Golde DW. Chronic myelogenous leukemia: new concepts (first of two parts). N Engl J Med. 1981;304:1201-1209.
35. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125-130.
36. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN. Chronic myelocytic leukemia: origin of some lymphocytes from leukemic stem cells. J Clin Invest. 1978;62:815-823.
37. Zhao RC, Jiang Y, Verfaillie CM. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood. 2001;97:2406-2412.
38. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003;100(suppl 1):11842-11849.
39. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2002;109:337-346.
40. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41-49.
41. Pelosi E, Valtieri M, Coppola S, et al. Identification of the hemangioblast in postnatal life. Blood. 2002;100:3203-3208.
42. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
43. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981-990.
44. Nishikawa SI, Nishikawa S, Hirashima M, Matsuyoshi N, Kodama H. Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development. 1998;125:1747-1757.
45. Hamaguchi I, Huang XL, Takakura N, et al. In vitro hematopoietic and endothelial cell development from cells expressing TEK receptor in murine aorta-gonad-mesonephros region. Blood. 1999;93:1549-1556.
46. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406-2414.